The NYT had a front page article on the decision by regulators in the United States and Europe to restrict access to Avandia, a major drug for treating diabetes. The reason for the restriction was a new study that linked the drug to tens of thousands of heart attacks.

This assessment was based on an independent analysis of data from GlaxoSmithKline, the manufacturer of the drug. GlaxoSmithKline did not do (or report) this analysis itself even though it had the data. The patent monopoly on Avandia granted by the government gave GlaxoSmithKline a strong incentive not to find the potential dangers of its drug. This failure of big government should have been noted in this article. (There are more efficient alternatives to patent monopolies for supporting prescription drug research.) 

Leave your comments

Post comment as a guest

0
  • No comments found

GuideStar Exchange Gold charity navigator LERA cfc IFPTE

contact us

1611 Connecticut Ave., NW
Suite 400
Washington, DC 20009
(202) 293-5380
info@cepr.net

let's talk about it

Follow us on Twitter Like us on Facebook Follow us on Tumbler Connect with us on Linkedin Watch us on YouTube Google+ feed cepr.net rss feed